In 2008, those were the Big Twenty pharma companies:
|
Major 20 Clinical Companies |
||
| 01 | Pfizer | $44,424 |
| 02 | GlaxoSmithKline | $38,501 |
| 03 | Sanofi-Aventis | $38,452 |
| 04 | AstraZeneca | $28,713 |
| 05 | Merck | $26,532 |
| 06 | Novartis | $25,477 |
| 07 | Johnson & Johnson | $24,866 |
| 08 | Roche | $21,998 |
| 09 | Eli Lilly & Co. | $17,638 |
| 10 | Wyeth | $17,179 |
| 11 | Bristol-Myers Squibb | $15,622 |
| 12 | Abbott Laboratories | $14,632 |
| 13 | Schering-Plough | $12,773 |
| 14 | Bayer Schering | $12,294 |
| Fifteen | Boehringer Ingelheim | $11,103 |
| 16 | Takeda | $10,626 |
| 17 | Astellas* | $8,530 |
| 18 | Daiichi-Sankyo* | $7,382 |
| 19 | Eisai* | $6,250 |
| 20 | UCB Group* | $4,370 |
The list looks a little different these days. For instance, Pfizer purchased Wyeth in January 2009, Merck purchased Schering in March 2009, and Roche signed a top deal with Genentech…confirming for many a trend toward consolidation in leading pharma. Which means that there are almost certainly more changes to come.
My take: With many block-buster products losing patent privileges, weak future product pipelines, slow market growth, tremendous litigation issues, an ever-increasing regulatory environment, and continued formulary tightening by insurance companies, medical companies are being battered and forced into mergers, buyouts, and massive layoffs in order to stay afloat. All that shifting and adjusting throws many sales reps right off the boat.
We’ve seen thousands of resumes from pharma sales reps who were already in pods calling on the same market area…so competition was already fierce when the market was nice. Mergers cause even more duplication in revenue territories, so pharma reps get laid off–the lucky ones get generous severance packages, but many get nothing. Trying to get another medical sales job in this set of circumstances is the definition of insanity– doing the same thing, but expecting to get different results. Because of the tremendous glut of these kinds of candidates searching for a career opportunity in a market that isn’t hiring because of the weak economy and other contributing factors (already noted), these candidates are not only out of a position, but they are really out of a career.
The answer is for the former clinical sales rep to evaluate, retool, and readjust to this new reality. Pharma sales reps often find obstacles when attempting to branch out into other areas of clinical sales, but I have placed many pharma reps into other healthcare revenue areas. The catch: they must accept that their skills may only get ‘em into an entry-level sales job. That’s a little difficult to swallow for some reps who’ve been around for a while. It’s not all negative–most of my client companies pay more in total compensation than the traditional clinical pay structure. But they also require strong skill sets, more technical skills, and very often more priceless old-fashioned elbow grease. Other areas of clinical revenue (pharma revenue, pharmaceutical device revenue, clinical diagnostics, imaging revenue, pathology sales, hospital equipment sales, biotech sales, etc.,) are a little harder to get into, but the results are worth it in compensation, respect, and job stability.
If you’re an out-of-work clinical revenue rep ready to start your career in a medical or healthcare-related company that requires real sales closers and pays for performance, apply here.
If you need personal career coaching to help you through this (and who wouldn’t?) then read this.
Article courtesy of Peggy McKee - Owner / Senior Headhunter at the nationally
recognized medical and pharma sales recruiting team of PHC Consulting.
© Copyright 2008 PHC Consulting | All rights reserved

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Top Twenty Pharmaceutical Company Changes Over the Last Eighteen Months: How They Affect Pharma Sales Reps”
Leave a Comment
You must be logged in to post a comment.